Vanda Pharmaceuticals (VNDA) Return on Capital Employed (2011 - 2026)
Vanda Pharmaceuticals (VNDA) reported Return on Capital Employed of 49.24% for Q1 2026, down 3583.0% on a YoY basis from 1.41% in Q1 2025, and down 30.26% sequentially from 37.8% in Q4 2025.
Vanda Pharmaceuticals (VNDA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 16 years of Return on Capital Employed data on file, last reported at 49.24% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3583.0% year-over-year to 49.24%; the trailing twelve-month figure through Mar 2026 stood at 49.24% (down 3583.0% YoY), and the FY2025 full-year result was 35.37%, down 2801.0% from the prior year.
- Return on Capital Employed fell to 49.24% in Q1 2026, from 37.8% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 4.76% in Q1 2022 to a low of 49.24% in Q1 2026.
- A 5-year average of 9.21% and a median of 4.52% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 120 bps in 2023 and tumbled 3583 bps in 2026, its largest moves.
- Tracing VNDA's Return on Capital Employed over 5 years: stood at 1.18% in 2022, then sank by 312 bps to 2.5% in 2023, then sank by 195 bps to 7.38% in 2024, then tumbled by 412 bps to 37.8% in 2025, then tumbled by 30 bps to 49.24% in 2026.
- Business Quant data shows VNDA's Return on Capital Employed at 49.24% in Q1 2026, 37.8% in Q4 2025, and 24.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -49.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.24% |
| Dec 31, 2025 | -37.80% |
| Sep 30, 2025 | -24.46% |
| Jun 30, 2025 | -19.89% |
| Mar 31, 2025 | -13.41% |
| Dec 31, 2024 | -7.38% |
| Sep 30, 2024 | -6.70% |
| Jun 30, 2024 | -5.82% |
| Mar 31, 2024 | -4.52% |
| Dec 31, 2023 | -2.50% |
| Sep 30, 2023 | -0.04% |
| Jun 30, 2023 | 1.74% |
| Mar 31, 2023 | 2.93% |
| Dec 31, 2022 | 1.18% |
| Sep 30, 2022 | 1.59% |
| Jun 30, 2022 | 2.94% |
| Mar 31, 2022 | 4.76% |
| Dec 31, 2021 | 8.23% |
| Sep 30, 2021 | 8.77% |
| Jun 30, 2021 | 8.46% |